Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 421

1.

Synthesis of Doxorubicin and miRNA Stimuli-Sensitive Conjugates for Combination Therapy.

Costa DF, Sarisozen C, Torchilin VP.

Methods Mol Biol. 2019;1974:99-109. doi: 10.1007/978-1-4939-9220-1_8.

PMID:
31098998
2.

Surface-engineered polyethyleneimine-modified liposomes as novel carrier of siRNA and chemotherapeutics for combination treatment of drug-resistant cancers.

Mendes LP, Sarisozen C, Luther E, Pan J, Torchilin VP.

Drug Deliv. 2019 Dec;26(1):443-458. doi: 10.1080/10717544.2019.1574935.

3.

Polymeric Co-Delivery Systems in Cancer Treatment: An Overview on Component Drugs' Dosage Ratio Effect.

Pan J, Rostamizadeh K, Filipczak N, Torchilin VP.

Molecules. 2019 Mar 15;24(6). pii: E1035. doi: 10.3390/molecules24061035. Review.

4.

Hydrogels and Their Applications in Targeted Drug Delivery.

Narayanaswamy R, Torchilin VP.

Molecules. 2019 Feb 8;24(3). pii: E603. doi: 10.3390/molecules24030603. Review.

5.

MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation.

Sarisozen C, Tan Y, Liu J, Bilir C, Shen L, Filipczak N, Porter TM, Torchilin VP.

J Drug Target. 2019 Jun - Jul;27(5-6):624-633. doi: 10.1080/1061186X.2019.1570518. Epub 2019 Jan 25.

PMID:
30656973
6.

Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.

Pan J, Mendes LP, Yao M, Filipczak N, Garai S, Thakur GA, Sarisozen C, Torchilin VP.

Eur J Pharm Biopharm. 2019 Mar;136:18-28. doi: 10.1016/j.ejpb.2019.01.006. Epub 2019 Jan 8.

PMID:
30633973
7.

Stimuli-Responsive Nano-Architecture Drug-Delivery Systems to Solid Tumor Micromilieu: Past, Present, and Future Perspectives.

El-Sawy HS, Al-Abd AM, Ahmed TA, El-Say KM, Torchilin VP.

ACS Nano. 2018 Nov 27;12(11):10636-10664. doi: 10.1021/acsnano.8b06104. Epub 2018 Oct 23.

PMID:
30335963
8.

The effect of low- and high-penetration light on localized cancer therapy.

Costa DF, Mendes LP, Torchilin VP.

Adv Drug Deliv Rev. 2019 Jan 1;138:105-116. doi: 10.1016/j.addr.2018.09.004. Epub 2018 Sep 12. Review.

PMID:
30217518
9.

Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy.

Costa DF, Torchilin VP.

Biomed Microdevices. 2018 Jul 12;20(3):59. doi: 10.1007/s10544-018-0298-0. Review.

PMID:
29998417
10.

Redox-triggered intracellular siRNA delivery.

Mutlu Agardan NB, Sarisozen C, Torchilin VP.

Chem Commun (Camb). 2018 Jun 14;54(49):6368-6371. doi: 10.1039/c8cc01376d.

PMID:
29869650
11.

Optimizing liposomes for delivery of Bowman-Birk protease inhibitors - Platforms for multiple biomedical applications.

Joanitti GA, Sawant RS, Torchilin VP, Freitas SM, Azevedo RB.

Colloids Surf B Biointerfaces. 2018 Jul 1;167:474-482. doi: 10.1016/j.colsurfb.2018.04.033. Epub 2018 Apr 20.

PMID:
29723819
12.

Polymeric micelles: Theranostic co-delivery system for poorly water-soluble drugs and contrast agents.

Upponi JR, Jerajani K, Nagesha DK, Kulkarni P, Sridhar S, Ferris C, Torchilin VP.

Biomaterials. 2018 Jul;170:26-36. doi: 10.1016/j.biomaterials.2018.03.054. Epub 2018 Mar 31.

PMID:
29649747
13.

Cytotoxicity of propolis nanopreparations in cancer cell monolayers: multimode of action including apoptotsis and nitric oxide production.

Sherif MS, Rehab TA, Hamdia ZA, Torchilin VP.

Gen Physiol Biophys. 2018 Jan;37(1):101-110. doi: 10.4149/gpb_2017023.

PMID:
29424355
14.

Phage-derived protein-mediated targeted chemotherapy of pancreatic cancer.

Wang T, Narayanaswamy R, Ren H, Gillespie JW, Petrenko VA, Torchilin VP.

J Drug Target. 2018 Jun - Jul;26(5-6):505-515. doi: 10.1080/1061186X.2017.1405424. Epub 2017 Dec 1.

15.

Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy.

Palmerston Mendes L, Pan J, Torchilin VP.

Molecules. 2017 Aug 23;22(9). pii: E1401. doi: 10.3390/molecules22091401. Review.

16.

d-α-Tocopheryl Succinate/Phosphatidyl Ethanolamine Conjugated Amphiphilic Polymer-Based Nanomicellar System for the Efficient Delivery of Curcumin and To Overcome Multiple Drug Resistance in Cancer.

Muddineti OS, Kumari P, Ghosh B, Torchilin VP, Biswas S.

ACS Appl Mater Interfaces. 2017 May 24;9(20):16778-16792. doi: 10.1021/acsami.7b01087. Epub 2017 May 15.

PMID:
28504884
17.

PEG-PE/clay composite carriers for doxorubicin: Effect of composite structure on release, cell interaction and cytotoxicity.

Kohay H, Sarisozen C, Sawant R, Jhaveri A, Torchilin VP, Mishael YG.

Acta Biomater. 2017 Jun;55:443-454. doi: 10.1016/j.actbio.2017.04.008. Epub 2017 Apr 8.

PMID:
28400314
18.

Applications of label-free, quantitative phase holographic imaging cytometry to the development of multi-specific nanoscale pharmaceutical formulations.

Luther E, Mendes LP, Pan J, Costa DF, Torchilin VP.

Cytometry A. 2017 May;91(5):412-423. doi: 10.1002/cyto.a.23102. Epub 2017 Mar 30. Review.

19.

The Cytotoxic Action of Cytochrome C/Cardiolipin Nanocomplex (Cyt-CL) on Cancer Cells in Culture.

Vladimirov YA, Sarisozen C, Vladimirov GK, Filipczak N, Polimova AM, Torchilin VP.

Pharm Res. 2017 Jun;34(6):1264-1275. doi: 10.1007/s11095-017-2143-1. Epub 2017 Mar 20.

PMID:
28321609
20.

Multifunctional Liposomes.

Aryasomayajula B, Salzano G, Torchilin VP.

Methods Mol Biol. 2017;1530:41-61. doi: 10.1007/978-1-4939-6646-2_3.

PMID:
28150195
21.

Gadolinium-Loaded Polychelating Polymer-Containing Tumor-Targeted Liposomes.

Erdogan S, Torchilin VP.

Methods Mol Biol. 2017;1522:179-192.

PMID:
27837539
22.

The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles.

Zou W, Sarisozen C, Torchilin VP.

J Drug Target. 2017 Mar;25(3):225-234. doi: 10.1080/1061186X.2016.1236113. Epub 2016 Oct 3.

PMID:
27616277
23.

Erratum to: Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model.

Pattni BS, Nagelli SG, Aryasomayajula B, Deshpande PP, Kulkarni A, Hartner WC, Thakur G, Degterev A, Torchilin VP.

Pharm Res. 2016 Nov;33(11):2845-2846. No abstract available.

PMID:
27599990
24.

Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.

Sarisozen C, Dhokai S, Tsikudo EG, Luther E, Rachman IM, Torchilin VP.

Eur J Pharm Biopharm. 2016 Nov;108:54-67. doi: 10.1016/j.ejpb.2016.08.013. Epub 2016 Aug 26.

PMID:
27569031
25.

Solid lipid nanoparticles co-loaded with doxorubicin and α-tocopherol succinate are effective against drug-resistant cancer cells in monolayer and 3-D spheroid cancer cell models.

Oliveira MS, Aryasomayajula B, Pattni B, Mussi SV, Ferreira LAM, Torchilin VP.

Int J Pharm. 2016 Oct 15;512(1):292-300. doi: 10.1016/j.ijpharm.2016.08.049. Epub 2016 Aug 26.

26.

Double-targeted polymersomes and liposomes for multiple barrier crossing.

Sánchez-Purrà M, Ramos V, Petrenko VA, Torchilin VP, Borrós S.

Int J Pharm. 2016 Sep 25;511(2):946-56. doi: 10.1016/j.ijpharm.2016.08.001. Epub 2016 Aug 3.

PMID:
27498281
27.

Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue.

Salzano G, Costa DF, Sarisozen C, Luther E, Mattheolabakis G, Dhargalkar PP, Torchilin VP.

Small. 2016 Sep;12(35):4837-4848. doi: 10.1002/smll.201600925. Epub 2016 Jul 19.

28.

Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model.

Pattni BS, Nagelli SG, Aryasomayajula B, Deshpande PP, Kulkarni A, Hartner WC, Thakur G, Degterev A, Torchilin VP.

Pharm Res. 2016 Oct;33(10):2540-51. doi: 10.1007/s11095-016-1978-1. Epub 2016 Jun 28. Erratum in: Pharm Res. 2016 Nov;33(11):2845-6.

29.

Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment.

Wang T, Narayanaswamy R, Ren H, Torchilin VP.

Cancer Biol Ther. 2016 Jun 2;17(6):698-707. doi: 10.1080/15384047.2016.1190488.

30.

Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey.

Sarisozen C, Salzano G, Torchilin VP.

Curr Pharm Biotechnol. 2016;17(8):728-40. Review.

PMID:
27033509
31.

Safety and efficacy of quadrapeutics versus chemoradiation in head and neck carcinoma xenograft model.

Lukianova-Hleb EY, Kim YS, Aryasomayajula B, Boulikas T, Phan J, Hung MC, Torchilin VP, O'Neill BE, Lapotko DO.

Am J Cancer Res. 2015 Nov 15;5(12):3534-47. eCollection 2015.

32.

Elucidating the role of free polycations in gene knockdown by siRNA polyplexes.

Klauber TC, Søndergaard RV, Sawant RR, Torchilin VP, Andresen TL.

Acta Biomater. 2016 Apr 15;35:248-59. doi: 10.1016/j.actbio.2016.02.021. Epub 2016 Feb 13.

PMID:
26884277
33.

Recent advances in siRNA delivery.

Sarisozen C, Salzano G, Torchilin VP.

Biomol Concepts. 2015 Dec;6(5-6):321-41. doi: 10.1515/bmc-2015-0019. Review.

PMID:
26609865
34.

Hypoxia-Responsive Copolymer for siRNA Delivery.

Perche F, Biswas S, Patel NR, Torchilin VP.

Methods Mol Biol. 2016;1372:139-62. doi: 10.1007/978-1-4939-3148-4_12.

PMID:
26530922
35.

siRNA Delivery by Stimuli-Sensitive Nanocarriers.

Salzano G, Costa DF, Torchilin VP.

Curr Pharm Des. 2015;21(31):4566-73. Review.

36.

Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid.

Kitatani K, Usui T, Sriraman SK, Toyoshima M, Ishibashi M, Shigeta S, Nagase S, Sakamoto M, Ogiso H, Okazaki T, Hannun YA, Torchilin VP, Yaegashi N.

Oncogene. 2016 May;35(21):2801-12. doi: 10.1038/onc.2015.330. Epub 2015 Sep 14.

37.

Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors.

Al-Abd AM, Aljehani ZK, Gazzaz RW, Fakhri SH, Jabbad AH, Alahdal AM, Torchilin VP.

J Control Release. 2015 Dec 10;219:269-277. doi: 10.1016/j.jconrel.2015.08.055. Epub 2015 Sep 3. Review.

PMID:
26342660
38.

Improved pharmacokinetics and enhanced tumor growth inhibition using a nanostructured lipid carrier loaded with doxorubicin and modified with a layer-by-layer polyelectrolyte coating.

Mussi SV, Parekh G, Pattekari P, Levchenko T, Lvov Y, Ferreira LAM, Torchilin VP.

Int J Pharm. 2015 Nov 10;495(1):186-193. doi: 10.1016/j.ijpharm.2015.08.079. Epub 2015 Sep 7.

39.

Improving Peptide Applications Using Nanotechnology.

Narayanaswamy R, Wang T, Torchilin VP.

Curr Top Med Chem. 2016;16(3):253-70. Review.

PMID:
26279082
40.

Intracellular Delivery of Nanoparticles with Cell Penetrating Peptides.

Salzano G, Torchilin VP.

Methods Mol Biol. 2015;1324:357-68. doi: 10.1007/978-1-4939-2806-4_24.

PMID:
26202282
41.

Systemic siRNA Nanoparticle-Based Drugs Combined with Radiofrequency Ablation for Cancer Therapy.

Ahmed M, Kumar G, Navarro G, Wang Y, Gourevitch S, Moussa MH, Rozenblum N, Levchenko T, Galun E, Torchilin VP, Goldberg SN.

PLoS One. 2015 Jul 8;10(7):e0128910. doi: 10.1371/journal.pone.0128910. eCollection 2015.

42.

Intratumoral Pharmacokinetics: Challenges to Nanobiomaterials.

Al-Abd AM, Al-Abbasi FA, Torchilin VP.

Curr Pharm Des. 2015;21(22):3208-14. Review.

PMID:
26027565
43.

New Developments in Liposomal Drug Delivery.

Pattni BS, Chupin VV, Torchilin VP.

Chem Rev. 2015 Oct 14;115(19):10938-66. doi: 10.1021/acs.chemrev.5b00046. Epub 2015 May 26. Review. No abstract available.

PMID:
26010257
44.

Cancer cell spheroids for screening of chemotherapeutics and drug-delivery systems.

Patel NR, Aryasomayajula B, Abouzeid AH, Torchilin VP.

Ther Deliv. 2015;6(4):509-20. doi: 10.4155/tde.15.1. Review.

PMID:
25996047
45.

Applications of polymer micelles for imaging and drug delivery.

Movassaghian S, Merkel OM, Torchilin VP.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Sep-Oct;7(5):691-707. doi: 10.1002/wnan.1332. Epub 2015 Feb 13. Review.

PMID:
25683687
46.

Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.

Salzano G, Navarro G, Trivedi MS, De Rosa G, Torchilin VP.

Mol Cancer Ther. 2015 Apr;14(4):1075-84. doi: 10.1158/1535-7163.MCT-14-0556. Epub 2015 Feb 5.

47.

Micelle-like nanoparticles as carriers for DNA and siRNA.

Navarro G, Pan J, Torchilin VP.

Mol Pharm. 2015 Feb 2;12(2):301-13. doi: 10.1021/mp5007213. Epub 2015 Jan 12. Review.

48.

Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors.

Essex S, Navarro G, Sabhachandani P, Chordia A, Trivedi M, Movassaghian S, Torchilin VP.

Gene Ther. 2015 Mar;22(3):257-266. doi: 10.1038/gt.2014.97. Epub 2014 Oct 30.

49.

Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery.

Torchilin VP.

Nat Rev Drug Discov. 2014 Nov;13(11):813-27. doi: 10.1038/nrd4333. Epub 2014 Oct 7. Review.

50.

Paclitaxel-loaded PEG-PE-based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce tumors.

Wang T, Yang S, Mei LA, Parmar CK, Gillespie JW, Praveen KP, Petrenko VA, Torchilin VP.

Mol Cancer Ther. 2014 Dec;13(12):2864-75. doi: 10.1158/1535-7163.MCT-14-0052. Epub 2014 Sep 19. Erratum in: Mol Cancer Ther. 2015 Jun;14(6):1517.

Supplemental Content

Loading ...
Support Center